Dieter Natlacen

Advising SENISCA on its partnership with L'Oréal

par Colin McCall et Charlie Adams

The Critical Medicines Act: A New Pillar of European Pharmaceutical Resilience

par Alina Krukover

China’s Rare Earth Export Controls: Implications for European Life Sciences Companies

par Dr. Amir-Said Ghassabeh

Life Sciences as a Security-Relevant Sector: Is Innovation at Risk under European and German FDI Control?

par Dr. Carolin Roßkothen, LL.M.

Corporate Venturing in Life Sciences: Making Partnerships Truly Strategic

Higher Regional Court of Frankfurt am Main on online referral of doctors for the prescription of medical cannabis

par Dr. Daniel Tietjen et Ennio Schwind, LL.M. Eur.

Request for a preliminary ruling by the BGH to the CJEU on the scope of the duty of care of medical device distributors

par Dr. Daniel Tietjen et Daniel Dietrich

Appeal proceedings on the admissibility of granting Rx bonuses to a mail-order pharmacy based in the EU

par Dr. Daniel Tietjen et Ennio Schwind, LL.M. Eur.

Federal Court of Justice (BGH): Placing medicinal products on the market within the meaning of Section 43 (1) of the German Medicines Act (AMG) when selling pharmacy-only medicines via the Amazon Marketplace

par Dr. Daniel Tietjen et Daniel Dietrich

Advising on Draig Therapeutics' US$140 million series A financing

par plusieurs auteurs